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Abstract
The combination therapy of the Artemisinin-derivative Artemether (ART) with Lumefantrine (LM) (CoartemH) is an important
malaria treatment regimen in many endemic countries. Resistance to Artemisinin has already been reported, and it is feared
that LM resistance (LMR) could also evolve quickly. Therefore molecular markers which can be used to track CoartemH
efficacy are urgently needed. Often, stable resistance arises from initial, unstable phenotypes that can be identified in vitro.
Here we have used the Plasmodium falciparum multidrug resistant reference strain V1S to induce LMR in vitro by culturing
the parasite under continuous drug pressure for 16 months. The initial IC50 (inhibitory concentration that kills 50% of the
parasite population) was 24 nM. The resulting resistant strain V1SLM, obtained after culture for an estimated 166 cycles
under LM pressure, grew steadily in 378 nM of LM, corresponding to 15 times the IC50 of the parental strain. However, after
two weeks of culturing V1SLM in drug-free medium, the IC50 returned to that of the initial, parental strain V1S. This transient
drug tolerance was associated with major changes in gene expression profiles: using the PFSANGER Affymetrix custom
array, we identified 184 differentially expressed genes in V1SLM. Among those are 18 known and putative transporters
including the multidrug resistance gene 1 (pfmdr1), the multidrug resistance associated protein and the V-type H+ pumping
pyrophosphatase 2 (pfvp2) as well as genes associated with fatty acid metabolism. In addition we detected a clear selective
advantage provided by two genomic loci in parasites grown under LM drug pressure, suggesting that all, or some of those
genes contribute to development of LM tolerance – they may prove useful as molecular markers to monitor P. falciparum
LM susceptibility.
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Introduction
Chemotherapy is a key strategy in the control of malaria. To
delay drug resistance, the current WHO recommendation is that
different antimalarials be employed in combinations that include
an Artemisinin derivative; this strategy is known as Artemisinin
Combination Therapy (ACT). The first line treatment for malaria
in many African countries is thus CoartemH which is composed of
the Artemisinin-derivative Artemether (ART) and Lumefantrine
(LM, Benflumetol) [1]. LM belongs to the quinoline-methanol (or
aryl-amino alcohol) group of antimalarials structurally similar to
Quinine (QN), Halofantrine (HLF) and Mefloquine (MFQ) [2].
Although CoartemH was hoped to reduce the speed of selecting
drug-resistant parasites, there is growing concern that resistance
may occur quickly, with LM perhaps even providing the main
selective pressure due to its extended elimination half-life
compared to that of the fast-acting ART [3].
Drug resistance is frequently linked to mutations and changes in
the expression levels of transport proteins [4–9]. In P. falciparum,
responses to quinolines and quinoline-methanols are associated
with PfCRT (chloroquine resistant transporter) and PfMDR1.
However, the exact mechanisms of drug action and development
of resistance to this group of antimalarials remain poorly
understood, and are sometimes contradictory. Although both
chloroquine (CQ) and the quinoline-methanol MFQ target the
parasite food vacuole, in vitro selection of MFQ resistance has been
shown to result in an increase in pfmdr1 copy number; at the same
time an increase in CQ sensitivity was observed [10–12]. In South
East Asian laboratory and field isolates, pfmdr1 amplification to up
to 5 copies is associated with decreased susceptibility to MFQ and
LM [13–19]; on the other hand LM resistance in African isolates
has been linked with CQ-sensitive PfMDR1 alleles (86N alone, or
together with 184F, 1246D or 76K) [20–22], with no apparent
pfmdr1 copy number changes.
The selection of CQ-sensitive alleles during treatment with
ART-LM suggests that this ACT could lead to the return of CQ
susceptibility in endemic areas. Indeed, genetic analysis of Kenyan
field isolates showed that parasites carrying wild type alleles at
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76 and pfmdr1
86 were the least susceptible to LM. However, we
found these wild type isolates to display a wide range of responses
to the drug (interquartile range IQR 93–202 nM) [23]. Therefore,
P. falciparum responses to LM are probably not attributable to
pfcrt
76and pfmdr1
86 alone, but may involve additional genes,
possibly transporters.
Although limited by the difficulty of obtaining stable, resistant
phenotypes, in vitro selection of drug resistant P. falciparum is an
important tool for identifying the genetic basis of antimalarial drug
resistance [24]. The efficiency of in vitro selection can be enhanced
by increasing the duration of in vitro culture but also through the
use of high initial parasitaemias of multidrug resistant strains; such
strains can acquire resistance at 10–1000 fold higher frequencies
than sensitive strains, a phenomenon known as ARMD or
accelerated resistance to multidrug [25,26]. The majority of such
P. falciparum selection studies with CQ, MFQ and Artemisinin,
suggests that the selection of drug-resistant parasites occurs in 2
stages: the first phase gives rise to an unstable, drug-tolerant
population followed by the selection of a truly stable phenotype.
The initial lines arise relatively quickly within days to months and
may be associated with gene amplification or deletion, or can
result from the differential expression of various genes including
the transporter PfMDR1 [26]. Changes in P. falciparum mRNA
expression levels are often of low amplitude, but they are highly
reproducible, dose-dependent and involve functionally related
genes, indicating that they do represent physiologically relevant
processes [27]. Therefore, at least some, perhaps many of the
mechanisms associated with unstable tolerance arising from in vitro
selection are similar to those that result in stable drug resistance in
the field.
In yeasts and bacteria, whole genome approaches have proven
valuable in the identification of key mechanisms underlying drug
action and development of resistance [28–30]. Here we used in
vitro drug selection to explore the mechanisms of LM resistance in
the human malaria parasite P. falciparum. We cultured the P.
falciparum isolate V1S – a multidrug resistant reference isolate
highly sensitive to LM – for 16 months (166 asexual cycles) under
varying, but steadily increasing concentrations of LM. At the end
of the selection regimen we used global transcriptome profiling of
the resulting drug-tolerant parasite isolate V1SLM and the
sensitive, parental V1S isolate to identify transcriptional changes
that arose during this medium-term selection regime. Our results
showed that the altered response of V1SLM to LM during the
establishment of this initial, unstable drug resistant phenotype was
associated with clear changes in expression levels of distinct genes;
these include known and putative parasite transporters and genes
encoding for components of fatty acid metabolism. Clearly,
additional genes (apart from PfMDR1 and PfCRT) may
contribute to the acquisition of LM tolerance and resistance in
vitro, and if validated, should be valuable molecular markers to
monitor susceptibility to LM and possibly other antimalarial drugs
in the field.
Results
In vitro Lumefantrine resistance (LMR) selection
Drug resistant P. falciparum isolates can be generated in vitro by
continuous culture in the presence of sublethal drug concentra-
tions [26]. Particularly, multidrug resistant (MDR) strains show a
high propensity to quickly adapt to drug pressure in culture [25].
Here, LMR was selected in the MDR reference strain V1S; V1S is
fully resistant to CQ and antifolate antimalarials but highly
sensitive to LM [31]. The V1S sensitive isolate displayed an initial
half maximal inhibitory concentration, LM IC50 of 24614 nM.
After 16 months (166 P. falciparum cycles) of continuous culture
under varying but increasing LM concentrations (Fig. 1) the
selected parasite line V1SLM grew in excess of 378 nM LM at a
rate comparable to that of the parent isolate V1S; this is 15 times
higher than the initial identified IC50. The LM IC50 of V1SLM was
elevated to 3267 nM. The intraerythrocytic development cycle
rates between the parent line (V1S) and the LM selected line
(V1SLM) were similar using the statistical likelihood based
approach described previously [32] (Fig. S1).When we finally
cultured V1SLM in drug-free medium, the IC50 returned to that of
the initial, parental strain V1S within 2 weeks, indicating a clearly
transient nature of resistance. After drug withdrawal, drug
pressure had to be re-introduced again gradually in a dose
escalating process starting from low concentrations and steadily
increasing drug concentration as parasites got accustomed again to
drug pressure.
Gene expression profiling in untreated and drug selected
parasites
Such rapid establishment of drug tolerance may rely on changes
in the transcriptional repertoire of the parasite rather than
mutations in specific genes. We sought to identify such adaptations
of the transient LM-tolerant phenotype V1SLM. We performed
global transcriptome profiling of V1SLM compared to V1S by
microarray analysis using the PFSANGER Affymetrix pseudo-
tiling array [32–35]. To this end RNA samples from 3 biological
replicates of V1S and V1SLM cultures (selected as outlined above)
were collected at 4 time points (0, 12, 24 and 36 hours) following
synchronization with sorbitol. These samples correspond to ring
forms, early and mature trophozoites, and schizonts. Out of the
initial 24 samples (12 for each line) probed by microarray
hybridization 19 were selected for final analyses as 3 showed
signs of RNA degradation (Fig. S2A) and 2 displayed a median
signal intensity that was out of range (Fig. S2B–D).
Identification of differentially expressed genes in V1SLM
by Linear Modeling
A linear modeling approach [36] was used to compare gene
expression profiles of V1S (control) and V1SLM (drug selected) pair
wise at each time point (0, 12, 24, and 36 hours) (Fig. 2); in order
to analyze expression profiles across the erythrocytic cycle (and
identify genes found to be DE across the entire time course) a
supplementary analysis using the EDGE program [37] was
employed.
Figure 1. Lumefantrine drug selection regimen. Number of cycles
during which V1S was cultured with varying Lumefantrine (LM)
concentrations. In total, parasites were exposed to LM for 166 P.
falciparum cycles, finally resulting in LM resistant V1SLM.
doi:10.1371/journal.pone.0031623.g001
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performed a pair wise comparison of gene expression in V1SLM
compared to V1S at each individual time point. An overall F test
of variance identified 589 genes out of the total of 5778 genes
represented on the array with an adjusted P,0.05 (Fig. 2A); this
corresponds to 10% of the total number of predicted P. falciparum
genes. 63% (371/589) displayed a minimum log 2 expression level
of 4 when averaged across all time points and both culturing
conditions. 266 genes were DE with a minimum fold change of 1.5
(Table S1), while 184 were DE between V1SLM and V1S in at
least one time point (Bayesian B.0); a total of 5189 genes
remained unchanged. Our analysis revealed a subset of transcripts
with opposite expression patterns, i.e. transcripts that were
gradually switched off across time (all subtelomeric and included
1 stevor,1 9rifins and 19 var genes) and transcripts that were
gradually turned on across time (consisting of ATP and GTP-
binding proteins, cell cycle regulators, kinases and phosphatase
and 4 transporters; marked by lateral blue and red bars in Fig. 2A
respectively). While the first cluster may simply be associated with
Plasmodium asexual development rather than be directly attribut-
able to the drug pressure [38], the latter cluster highlights the up-
regulation of transporter proteins under drug pressure.
Moreover, approximately L (135/192) of all DE genes were
seen at ring stage (0 h), while only 15, 14 and 28 emerged DE at
12 h, 24 h, and 36 h, respectively (Fig. 2B). The majority of DE
genes were down-regulated at ring stage (101/144) while up-
regulation was mainly observed in later time points (14/24 at 12 h,
12/14 at 24 h and 38/56 at 36 h). Among the most highly DE
genes were those involved in antigenic variation (34, mainly at ring
stages), transcription/translation (23), fatty acid biosynthesis (7)
protein binding/folding (12), proteolysis (7), and those with a
function in transport (14; annotated as such or containing at least 7
trans-membrane domains). Gene Ontology (GO) analysis (P.
falciparum annotations downloaded in March 2010 at www.
geneontology.org) (Fig. 3) revealed that at ring stage there was
significant (P,0.05) over-representation of genes involved in
transport activity [both by molecular function (MF) and Biological
Process (BP)], phosphatidyl-inositol metabolic processes (BP),
ubiquination (BP), and transferase activity (MF). At 12 h, genes
involved in DNA polymerase activity were significantly over-
represented whilst from 12–36 hours most of DE genes were those
involved in fatty acid metabolic processes (BP).
Known and candidate transporters are DE
Often, transporters are associated with drug resistance pheno-
types [28–30]. 2.5% of all P. falciparum genes are predicted to
encode transporter proteins with typically 7 or more (predicted)
transmembrane (TM) domains; only few contain less than 7 [39].
Here we included those annotated as transporters (www.plasmodb.
org) and proteins with at least 7 TM domains. Globally, our
microarray analysis identified 18 candidate transporters (Table
S2); linear modeling identified 14 genes, while the EDGE program
highlighted a further 4.
Of those transporters identified by linear modeling, 8 were
down-regulated at ring stage (including PfSR25/MAL7P1.64
which has been reported to be constitutively expressed in blood
stages [40]), 1 up-regulated at late trophozoite stage, 4 and 1 were
up and down-regulated in schizonts, respectively (Table S2, Table
S1). After text mining and GO enrichment analyses, several of
these identified transporters were of special interest: PfVP2
(PFL1700c), a folate/biopterin transporter (PF11_0172), the sugar
transporter PFI0785c, the P-type ATPase PFC0840w and
PfMRP1 (PFA0590w) were all over-expressed in late time points
whilst PFI0720w (a putative 11 TM transporter of the Major
Facilitator Superfamily) was clearly down-regulated at 36 h.
PfVP2, sugar transporter PFI0785c, P-type ATPase PFC0840w,
and PfMRP1 similarly displayed a gradual increase in expression
during the intra-erythrocytic cycle in V1SLM as compared to V1S
(red marked cluster in Fig. 2A).
Four additional genes annotated to have transport functions
were identified in our analyses; these included an ADP/ATP
Figure 2. Changes in gene expression profiles between LM
resistant V1SLM and LM sensitive V1S P. falciparum.A .Heatmap
of 589 expressed genes showing Differential Expression (DE) in at least
one time point (F adjusted p,0.05). The 2 clusters highlighted with
blue and red bars on the right hand side of the heatmap correspond to
subtelomeric genes gradually switched off in the presence of LM, and
transporters and cell cycle regulators gradually turned on in the
presence of LM, respectively. Log2 ratio of V1SLM vs. V1S expression is
indicated by the color key ranging from 26 (blue, under-expression) to
6 (red, over-expression) B. Venn diagram showing the asexual life cycle
distribution of DE genes. Analysis was based on linear modeling using
Limma package of R/Bioconductor.
doi:10.1371/journal.pone.0031623.g002
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mitochondrial inner membrane translocases PF13_0300 and
PF13_0358, and an oxoglutarate/malate translocator protein
(PF08_0031).
The EDGE analysis identified 4 more genes containing 7 or
more TM’s: PFE1525w and PFL0220c (both conserved Plasmodium
membrane proteins with unknown function), PFE0825w (a
putative metabolite/drug transporter) and the putative sugar
transporter PFE1455w.
From the 18 DE candidate transporter genes (Table S2), 5 were
chosen for qRT-PCR analyses to confirm the microarray results
(Fig. 4, Table S2). Transcript levels of PfMDR1 (PFE1150w),
known to be associated with LM resistance, were also assayed and
showed over-expression at 12 h. Although not significantly (F-test,
p=0.14), this transcript was over-expressed at 24 h in V1SLM by
microarray analysis. All significant genes identified by linear
modeling were confirmed to be DE in at least one time point
between V1S and V1SLM. Only 1 out of 10 genes (PFE1525w)
identified by the EDGE analysis did not show differential
expression by qRT-PCR.
Genes involved in fatty acid metabolism
Interestingly, GO analysis revealed a significant over-represen-
tation of DE genes involved in fatty acid metabolism in V1SLM
Figure 3. Gene Ontology (GO) analysis at main time points of the P. falciparum asexual life cycle. The time points color legend is indicated
at the top left corner of the barplot. GO enrichment is indicated as stacked percentages.
doi:10.1371/journal.pone.0031623.g003
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PF08_0031) are predicted to be involved in phospholipid and
dicarboxylic acid transport (BP and MF), respectively. Other genes
identified are: PF13_0128 (a beta-hydroxyacyl-ACP dehydratase
precursor), PF13_0285 (an inositol-polyphosphate 5-phosphatase),
the phosphatidylinositol synthase MAL13P1.82, PF10_0016 (an
acyl CoA binding protein isoform 2, ACBP2) and PF10_0015 (an
acyl CoA binding protein, isoform 1, ACBP1).
Chromosomes 2 and 10 ends are retained in long term in
vitro culture
Several consecutive genes on the left arms of chromosomes 2
and 10 showed consistent up-regulation in all time points in
V1SLM when compared to the parental isolate V1S; this
observation was statistically significant for 6 and 7 of those genes
on chromosomes 2 and 10, respectively (Fig. 5; Table S1). As P.
falciparum gene expression is thought to be exclusively monocis-
tronic [41], we speculated that the up-regulation is due to the loss
of these loci in untreated parasites during culture. A segmentation
algorithm, run at the probe level, confirmed clearly that the left
arms of chromosomes 2 and 10 were amplified in V1SLM
compared to V1S (P,0.01), suggesting that the control line V1S
could have lost these portions of the chromosomes after long term
in vitro culture (Fig. 5A and B). For that reason we included
PFB0105c (chromosome 2) and PF10_0017 (chromosome 10) to
confirm the observed under-expression and possible deletion of the
left arm of chromosomes 2 and 10 in V1S. Quantitative PCR
(qPCR) using cDNAs and genomic DNAs isolated from V1S and
V1SLM at the end of the 16-month culture period showed a signal
of amplification for PF10_0017 in the drug-resistant isolate while
no signal was found in the parental line V1S. PFB0105c was 4–21
times more expressed in V1SLM than in V1S, with a good degree
of agreement between qRT-PCR and microarray analysis (global
correlation coefficient r=0.74, Fig. 4 and Table S3). Among the
genes that were shown to be significantly DE by microarray and
qPCR analysis are members of multigene families, including
PHIST proteins (PFB0105c, PHISTc and PF10_0017, PHISTa).
Discussion
In this work, we report the in vitro selection of lumefantrine (LM)
resistance. We have selected a parasite line that grows in the
presence of high LM concentrations, although its IC50 remains
low. This feature has been observed with other antimalarials
(mainly mefloquine) and we have discussed this phenomenon in
detail [26]. This likely results from the methodology used to
determining IC50’s (see Material and Methods) and the presence of
more than one parasite population with different drug sensitivities.
During drug selection resistant parasites will outgrow sensitive
ones, while in the absence of drug, the opposite is observed (the
resistant ones are outgrown by the sensitive ones); hence the
observed low IC50. This highlights the limitation of current
protocols of antimalarial chemosensitivity testing in detecting
subtle changes in drug susceptibility in vitro, a limitation that has
also been discussed elsewhere [42]. Nevertheless, such subtle
changes most likely represent biologically relevant mechanisms as
they may be similar to the changes occurring after exposure to
sub-therapeutic levels of LM (during the long elimination phase of
LM in vivo). It has been proposed that the exposure of parasites to
such sub-therapeutic LM levels during this phase (in the absence of
ART) provides the main selective pressure for resistance to
CoartemH [3]. The unstable V1SLM resistant phenotype we
observed here is similar to previously reported phenotypes in
antimalarial drug selection experiments [26]. More recently
resistance to the potent antimalarial drug Artemisinin was
described in vitro (associated with selection of dormant forms)
[42] and in vivo (associated with prolonged parasite clearance
times) but with no corresponding decrease in in vitro susceptibility
to Artemisinin [42,43]. However, as the growth rate of LM
selected parasites was comparable to that of the parent line, the
mechanism may not be similar to that observed for Artemisinin
resistance in vitro in these studies [43,44].
Gene expression profiling and drug resistance
The utility of gene expression profiling to identify mechanisms
of antimalarial drug action and resistance is controversial. Several
studies reported low amplitude mRNA changes after in vitro
exposure of parasites to CQ and antifolates with no apparent link
to the drugs’ presumed modes of action [44–46], while others
observed biologically relevant responses after exposure to CQ
[47], tetracyclines [48] or Artesunate [49]. However, despite low
amplitudes these changes were dose-dependent and highly
reproducible, supporting physiologically relevant processes involv-
ing functionally related genes [27]. Our results also show relatively
small alterations in gene expression (2–4 fold at the most) after LM
treatment, which could reflect tightly controlled mechanisms of
gene regulation in malaria parasites in response to drugs.
Alternatively, this may indicate that synergisms of multiple genes
Figure 4. Correlation coefficients of log2 fold changes (FC) by RT-qPCR and microarray analysis. The linear regression is indicated on the
plot, with an r
2=0.7389.
doi:10.1371/journal.pone.0031623.g004
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31623Figure 5. Chromosomes 2 (A) and 10 (B) show over-expression of contiguous probes covering 21 and 22 CDS, respectively.
Amplification of the signals for the left arms of chromosomes 2 (A) and 10 (B) are enlarged for each time point as indicated. Every single coloured dot
corresponds to a 25-mer probe: red is for 0 h, blue for 12 h, green for 24 h and yellow for 36 h. Underneath every enlarged chromosomal arm are
pink bars indicating 100% robustness of signal amplification at p,0.01 (using SnoopCGH program with Smith–Waterman algorithm implementation).
A normal distribution of the log ratios (y-axis) around the zero horizontal line is expected if the expression levels are the same along the chromosome
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response rather than relying on a clear-cut, adaptive signature.
In our study linear modeling analysis, non-hierarchical cluster
analysis and GO enrichment of gene expression data highlighted
genes associated with fatty acid metabolic processes and transport
(7 and 14 genes respectively), and identified chromosomal changes
between treated and untreated cultures. Of the 14 candidate
transporters, 11 are annotated as transporters or translocators
(www.plasmodb.org), and 8 had previously been associated with
drug resistance, especially CQ [46,47,50]. Having been linked to
drug responses (see below) support the notion that many of the
newly identified genes here are indeed involved in LM tolerance.
The repeated identification of similar genes using different
methodologies strongly suggests that such adaptations are specific
and biologically relevant; therefore they provide useful insights in
understanding the response of P. falciparum to LM, and
antimalarial drugs in general. As for the other genes, their
localization and identification as part of the permeome, make
them potential candidates for transporting drugs in and out of the
cell [39].
Transporter up-regulation after 16-month culture with
LM
Parasites treated with sublethal CQ showed the putative P-type
ATPase PfATPase7 (PFC0840w) and the V type-H+ pyrophos-
phatase PfVP2 (PFL1700c) to be DE [47]. Both genes were up-
regulated in our analysis at 36 h. PfVP2 belongs to a novel class of
plant and protozoan H+ pumps [51] and is localized to the
digestive vacuole as well as the parasite plasma membrane [52],
but was also found on the infected RBC membrane [53]. If the
protein acts as an active pump responsible for the extrusion of
protons from the parasite it would help maintain cytosolic pH
balance together with PfATPase7, PfCRT and PfMDR1. This
would explain the observed over-expression in response to LM
here, and CQ in earlier studies.
We also observed an over-expression of pfmdr1 (PFE1150w) in
the LM-selected line V1SLM by microarray analysis (albeit not
statistically significant) and qPCR. pfmdr1 copy number changes
[13,17–19] and point mutations [20,21,54,55] are often associated
with LM resistance, while increased pfmdr1 transcript levels have
been linked to quinoline-based drugs [49,56,57] and artemisinin
[49], but not to the antifolate pyrimethamine. The up-regulation
of pfmdr1 may therefore be specific to only a certain group of
antimalarials.
The ABC transporter pfmrp1 (PFA0590w) was similarly up-
regulated in mature parasites (24 h time point and later) consistent
with its wild type transcriptional peak as measured by RNAseq
[38]. The protein is localized to the plasma membrane and vesicles
of trophozoite, ring and merozoite stages [58,59], and is
homologous to the human multidrug associated protein 2
(MRP2) [59], a major cause of cancer chemotherapy failure [5].
Deletion of pfmrp1 in the CQ-resistant parasite W2 resulted in
reduced parasite fitness in vitro, increased accumulation of
radioactive glutathione and sensitivity to QN, CQ, piperaquine
(PQ), MFQ and Artemisinin [58]. These effects may be attributed
to an impaired ability to transport drugs and toxic metabolites
suggesting that PfMRP1 is a molecular pump, which removes
drugs and toxic metabolites from the parasite. Indeed, parasites in
which PfMRP1 was disrupted accumulated higher levels of CQ
and QN than wild type parasites [59]. The relatively small change
in IC50 (2 fold) in PfMRP1 disrupted parasites in the cited study
[58] suggests that PfMRP1 may rely on a functional interplay with
other transporters in mediating drug resistance.
The expression levels of several transporters (PfMRP1,
PfATPase7, PfVP2 and PFI0785c, Table S1) increased gradually
as the erythrocytic cycle progressed from 0 to 36 h in V1SLM (LM
treated parasites) compared to V1S (control parasites), suggesting
that the differential expression observed was indeed a consequence
of LM pressure. Our microarray analysis also showed that 6 of the
18 transporters were up-regulated by at least 1.5 fold at mature
stages (24 h–36 h, Table S2).This agrees with the proposed mode
of action of LM which like other quinoline antimalarials is thought
to interfere with heme polymerization which peaks in mature
parasites [60,61].
Could increased fatty acid synthesis counteract impaired
membrane recycling?
The quinoline-methanols MFQ and QN are known to bind
with high affinity to membrane and purified phospholipids,
suggesting that these molecules may indeed be biological targets
[62–66]. These drugs are thought to exert their antimalarial effects
by impairing membrane recycling within the endo-lysosomal
system of the intracellular parasite [67–69], ultimately blocking
heme degradation and causing death. LM is structurally similar to
QN and MFQ. Therefore, increased fatty acids biosynthesis in
V1SLM parasites could compensate for impaired membrane
recycling induced by LM pressure. An altered expression of few
fatty acid metabolism genes (including PF10_0016 identified here)
has also been reported after exposure of malaria parasites to CQ
[70] and ART [49]. This observation further supports the view
that analyzing the transcriptome can provide biologically mean-
ingful information about the response of malaria parasites to drug.
Retention of frequently lost chromosome ends provides
a selective advantage during drug pressure
Deletion of approximately 100 kb of the left arm of chromo-
some 2 is known to occur spontaneously in laboratory and field
isolates after short term culture [71–75]; our microarray data
showed a clear over-expression of several consecutive genes from
this locus in V1SLM while V1S lost this segment of the
chromosome. However, qPCR carried out on both cDNAs and
genomic DNAs showed low levels of expression of PFB0105c in
V1S, suggesting that the V1S line was not clonal and had already
been deleted in some parasites. Long-term LM exposure
subsequently resulted in the selection of parasites carrying this
locus in the V1SLM line. None of the genes from this locus have
been linked to provide a selective advantage to grow under LM
resistance. Similarly, 130 kb were deleted on the left arm of
chromosome 10. Copy number variations (CNV) of 3 genes within
this segment (PF10_0013, PF10_0014 and PF10_0023) have
previously been reported in lab [73,74] and field isolates [74] after
short term culture. Four of the other over-expressed genes
(PF10_0015, PF10_0016, PF10_0019 and PF10_0021) were found
deleted in parasites treated with sub-lethal concentrations of CQ
[70]. Our qPCR experiments detected no signal for PF10_0017 in
the V1S parental line but clear amplification in V1SLM using both
cDNAs and gDNAs as templates, corroborating the absence in
(indicated as kilo base pair [kbp]). The CDS (represented under each chromosome by blue rectangles) contained within each amplified region are
indicated on the right with their appropriate annotation (www.genedb.org). The genes marked with an * have been found significant at B.0 in the
pairwise comparisons of the microarray data in at least one time point, while the underlined genes have been double checked by qRT-PCR.
doi:10.1371/journal.pone.0031623.g005
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been described previously between CQ and amino alcohols such
as LM [10–12,23] may explain the opposite effects observed in this
region of chromosome 10 whereby CQ pressure led to selection of
parasites carrying the deleted genes in the cited study [70], whilst
LM pressure led to selection of parasites carrying this region in our
study.
Both segments of chromosomes 2 and 10 identified here carry
the Plasmodium exported proteins (PHIST). Moreover, 5 other
PHIST transcripts were found significantly DE in our analysis,
prompting us to speculate that they may play a role in regulating
the transport of substances and possibly drugs such as LM.
However, further studies are needed to confirm the specific role of
these gene deletions on chromosomes 2 and 10 in promoting LM
resistance. Interestingly, a novel candidate gene (PF10_0355) was
recently demonstrated to modulate resistance to LM and
structurally related antimalarials, re-enforcing the notion that
novel genes may indeed play an important role in antimalarial
resistance (Van Tyne et al, 2011).
Influence of genetic backgrounds on drug testing
We chose V1S (a multidrug resistant line sensitive to LM) as our
parent isolate because in vitro multi-drug resistant isolates are
known to acquire resistance faster than sensitive ones. Of course,
the genetic background of the parasite can influence the
acquisition of drug resistance [50,76] and LM adaptations
observed here may vary in other isolates. Here, the resultant
V1SLM resistant population grew steadily in high concentrations of
LM, although the IC50 was only marginally increased and the
phenotype ultimately transient. The comparison of these data with
those obtained from additional tolerant or resistant isolates from
diverse genetic backgrounds will shed further light on whether LM
resistance varies according to the genetic background of the
parasite. We compared the expression profile of V1S with that of
the drug-selected line V1SLM while under sub lethal concentra-
tions of LM. A comparison of these expression data with those
obtained from the V1S parent growing in the presence of LM at
the time of sampling may provide insight into direct transcriptional
effects of LM on parasites as opposed to the long-term effects of
LM drug selection. Furthermore, beginning selection with a
diverse mixture of parasites may increase the chances of selecting a
parasite line with a genetic background against which stable
resistance can develop.
In conclusion, this study has identified 18 candidate transport
proteins (other than PfCRT and PfMDR1) that are potentially
involved in modulating the LM response of P. falciparum. We also
observed the over-representation of genes involved in fatty acid
metabolism supporting the prevailing hypothesis that LM exerts its
antimalarial action by interfering with membrane phospholipids.
In addition, our data highlight an over-expression of consecutive
genes on the left arms of chromosomes 2 and 10 (some of which
were previously observed to be deleted in laboratory and cultured
field isolates), suggesting that these genes may have a role, even if
indirect, in mediating antimalarial drug resistance. Interestingly,
an opposite effect of CQ and LM on several genes on the left arm
of chromosome 10 was documented. This study demonstrates that
the analysis of the expression profile of malaria parasites under
drug pressure may provide biologically important insights on drug
response that will be useful for the immediate field. More
functional studies and the analysis of field isolates are required
to clarify the exact function of the transport proteins, fatty acid
metabolism genes and chromosomes 2 and 10 deletions in
mediating resistance to LM and other antimalarials. Further
validation is needed to confirm if the genes identified in our study
can be used as robust molecular markers to track LM resistance in
endemic settings.
Methods
Selection of drug resistance in vitro
To select LM resistant parasites in vitro we cultured V1S isolates
(multi-drug resistant strain sensitive to LM) continuously under
varying concentrations of LM. Initially, parasites were maintained
in culture according to Trager and Jensen methods [77] at
concentrations higher or equal to the IC99 (inhibitory concentra-
tion that kills 99% of parasites). Parasites were cultured in 30 ml
medium in 75 cm
2 culture flasks at initial parasitaemias of 5–10%
and 4–6% haematocrit. This process was continued and the drug
pressure varied after each 48 hr cycle depending on the
parasitaemia and the viability of the parasites (observed under a
microscope), i.e. when parasitaemia was ,0.5% the drug pressure
was reduced to as low as IC10, and then raised steadily to
concentrations higher or equal to the IC99 once growth had
resumed. To ascertain that growth had resumed, the parasites
were maintained in culture under decreased drug pressure until
parasitaemia had increased 2 to 3 fold. Thereafter M of the
culture was subjected to another drug selection cycle. Parasites
were scored as growing steadily in drug if growing exponentially in
a drug concentration for 3 or more consecutive cycles. Parasites
were cryopreserved at each selection cycle when growth rate had
resumed. At first, the cycle between relieving the parasites of drug
pressure and resumption of normal growth could last 2 to 3 weeks
after which the growth rate increased steadily after a period of
continuous drug pressure.
IC50 determination
To assess the IC50 of the selected line, the culture medium was
removed and the resulting pellet re-suspended in complete culture
medium, thus relieving the parasites of drug pressure. The
parasites were then maintained in routine culture over a period
of 10–14 days in the absence of drug. Thereafter, the IC50 of the
parasite was determined to assess the stability of the resistant
phenotype.
Chemosensitivity testing
LM was dissolved in 90% methanol plus 10% HCl. Chemo-
sensitivity assays were carried out in 200 ul cultures containing
0.5% parasitaemia and 1.5% haematocrit in 96 well microtitre
plates. The prepared test plates were incubated at 37uCi na
humidified airtight box flushed with 3% CO2,5 %O 2, 92% N2
mixture. After one cycle (48 hrs), 25 ul of tritiated hypoxanthine,
(3H-hypoxanthine, 0.5 uCi) diluted in culture media was added to
each well and incubated for a further 18 hrs. Well contents from
each plate were then harvested onto glass fibre filter mats using a
96 well cell harvester (TomTec Inc and Perkin-Elmer) and the
amount of ionizing radiation determined using a Wallac 1450
Microbeta counter. Results were expressed as the LM concentra-
tion required for 50% inhibition of
3H incorporation into parasite
nucleic acid (IC50) obtained by non-linear regression of the dose
response curve.
Cultivation of parasites for microarray transcriptome
analysis
Cultures of V1S (control) and V1SLM growing steadily in
142 nM LM (a concentration 66the IC50 of the parent line V1S)
were maintained in 75 cm
2 culture flasks at 2% haematocrit and
50 ml volume according to standard culture protocols [77]. Once
a good growth rate of at least 2–3 fold increase after every cycle
Lumefantrine Response in Malaria Is Multigenic
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nized with sorbitol at each subsequent cycle and diluted with O+
red blood cells until 10 such flasks were generated and
parasitaemia of 8–10% achieved in each flask. Thereafter, 1 ml
infected RBC was sampled at the start of an erythrocytic cycle by
centrifuging the contents of one flask in a 15 ml centrifuge tube at
1500 g, and every 12 hrs throughout the 48 hr-cycle. For each
sample, once centrifuging was complete, the supernatant was
removed from the centrifuge tube and the resulting pellet dissolved
in 5 ml of Trizol LS reagent (Invitrogen) then kept at 280uC. This
sampling experiment was repeated thrice on different days both
V1S and V1SLM to generate 3 biological replicates.
RNA and DNA extraction
RNA was extracted with phenol-chloroform according to a
published protocol [78]. Genomic DNA was extracted from
saponin-lysed parasite pellets using a commercial genomic DNA
extraction and purification Kit (Qiagen).
Microarray analysis
All microarray experiments were performed at the Wellcome
Trust Sanger Institute, Cambridge, UK using the PFSANGER
high density custom tiling-like arrays and following the Sanger
Institute Affymetrix protocol [34]. PFSANGER Affymetrix arrays
are 25-mer custom designed, covering both strands of P. falciparum
3D7 strain, coding and non-coding sequences, for a total of ,2.5
million probes specific for P. falciparum. A total of 24 RNA samples
generated from 3 biological replicates of synchronized V1S and
V1SLM parasites in culture at 4 time points (0 h, 12 h, 24 h and
36 h) were treated with Turbo DNAse enzyme (AmbionH)
according to manufacturer’s instructions to remove any contam-
inating DNA. RNA samples were then quantified and analyzed for
quality using the Agilent RNA 6000 Nano Kit (Agilent
Technologies). Once the integrity of the RNA was ascertained,
double stranded cDNA was synthesized from 8 mg of each RNA
sample according to the Affymetrix Eukaryotic gene expression
protocol. cDNA was then used as a template in an in vitro
transcription reaction (IVT) to produce amplified amounts of
biotin-labelled complementary RNA (cRNA). 20 ug of cRNA
from each time point was fragmented to 25–200 bp fragments
after which 15 ug of fragmented cRNA was hybridized onto a
PFSANGER microarray as recommended by Affymetrix. Hybrid-
ization, washing, staining and scanning was as recommended by
the manufacturer. The hybridization intensity for each 25 bp
feature from each scan was computed using the Affymetrix
software suite. The microarray data was then preprocessed with
Bioconductor software and R (www.r-project.org). The arrays
were RMA background subtracted, quantile normalized, median
polished according to methods previously described [79], and
summarized according to the June 2007 release of P. falciparum
genome annotation, representing a total of 5363 genes. Micro-
array data were submitted to ArrayExpress under the accession
number E-TABM-1101.
Data mining
An average of 1.5 fold differences in expression of V1SLM
relative to V1S was applied as a cut off point for up or down
regulation after fitting a linear model to the microarray data
(limma package [80]). The cut-off for statistical significance was set
at p,0.05. GO enrichment analysis was performed using the
GOstats Bioconductor package ([81]). In addition supplemental
EDGE analysis [37] was done to identify additional and
potentially useful transporter genes. For the segmentation analysis
of chromosomes 2 and 10 deletions SnoopCGH software [82] was
used with Smith–Waterman algorithm implementation at P,0.01.
cDNA synthesis
RNA used for cDNA synthesis was obtained from the same V1S
(control) and V1SLM (we used the same RNA for RT-qPCR
that was used for microarray analysis). For each sample, 5 ug of
RNA were used to synthesize cDNA using OligodT16 and
Bioscript
TM reverse transcriptase according to the manaufacturer’s
instructions.
Selection of candidate transporters for confirmation by
qRT-PCR
PF10_0210 was chosen as control for all qPCR experiments, as
its expression did not vary greatly throughout the cycle in both the
V1S (control) and V1SLM (drug treated) parasites. Primers were
designed based on the mRNA sequences obtained from PlasmoDB
(http://www.plasmodb.org/) using primer 3 primer version 0.4.0
primer design software (http://frodo.wi.mit.edu/primer3/) (Table
S4). Products were all between 100–150 bp in length, and as much
as possible stringent criteria were set to limit self annealing or
formation of primer dimmers. qPCR experiments were performed
on a Corbett Robotics CAS-1200
TM precision liquid handling
system (Corbett Life sciences). Each 10 uL amplification reaction
was done in 10 uL strips containing 1 uL template, 167 nM/L of
forward and reverse primers and 5 uL of SYBRH Green PCR
Mastermix (supplied as 26concentration mix containing SYBRH
green I dye, AmplitaqH Gold DNA polymerase, dNTPs with
dUTP, passive reference dye and optimized buffer components).
Quantitative PCR reactions were done on a Corbett Rotor-gene
6000 thermo-cycler (Corbett Life sciences) and consisted of 95uC
for 10 minutes followed by 50 cycles of 95uC for 25 seconds, 58uC
for 25 seconds, and 68uc for 30 seconds. Melting analysis of PCR
products was done as follows: ramp from 50–99uC rising by 1uC
each step, wait 90 seconds of Premelt conditioning on 1
st step, and
5 seconds each step afterwards. Corresponding V1S (control) and
V1SLM (drug selected) cDNA samples were quantified in the same
real time PCR run for each control and candidate gene. For each
sample, PCR reactions were done in duplicate. To facilitate
relative quantification, a standard curve was generated for each
gene by including 4 serial dilutions of 3D7 genomic DNA
spanning a wide dynamic range (1:1, 1:100, 1:10000, 1:1000000)
in each run. For the two genes on chromosomes 2 and 10, qPCR
experiments were repeated the same way using gDNA as template
to estimate gene copy numbers.
For each sample, the following formula was used to calculate
relative expression (fold change, FC) between V1S (control) and
V1SLM (drug selected):
FC~ expression of candidate gene V1SLM ðÞ { expression of control ð ½
gene PF14 0210 V1SLMÞ = expression of candidate gene ð ½
V1SÞ= expression of control gene PF14 0210 V1S ðÞ  
Supporting Information
Figure S1 The intraerythrocytic developmental cycle
rates of V1S and V1SLM. The maximum likelihood estimates
(MLEs) and 95% confidence intervals of the samples are shown.
Samples are ordered in the y dimension according to the MLE of
hours post invasion (HPI). The MLEs of V1S and V1SLM samples
are shown to be comparable across the time course.
(PDF)
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and microarray datasets (24 samples). A. Agilent Bioana-
lyser electrophoresis file run summary of total RNAs. 3 samples
were degraded (blue arrows) and not hybridised on PFSANGER
arrays. B. Boxplot analysis of the raw data following hybridisation.
C. RNA degradation plot. D. Principal Component Analysis plot
of the 21 samples prior to remove outliers (indicated by red
arrows). Plots were generated in R using the ‘‘affycoretools’’
package.
(PDF)
Table S1 All genes with F adjusted P,0.05 (589 genes),
average expression AveExpr.log2(4) (371 genes), fold
change of at least 1.56 (20.58,log2Ratio,0.58; 266
genes) and with a Bayesian B.0 in at least one time
point (192) are listed. ID=Plasmodium falciparum gene ID.
log2Ratio=log base 2 of fold change ratio between V1SLM and
V1S. B=log odds of DE. AveExp=average expression of a given
gene across the whole experiment. F.adj.P.Val=P values adjusted
for multiple testing. Product description, TM (number of
transmembrane domains), SP (presence of a signal peptide) and
GO annotations were taken from www.plasmodb.org.
(PDF)
Table S2 Known and putative transporters identified by
microarray analyses to be differentially expressed
during LM transient drug resistance acquisition. TM,
transmembrane domains; SP signal peptide; AP apicoplast
targeting signal; qP verified independently by qPCR; RNAseq
optimal time of expression as determined by RNAseq [38]; linear
modeling for each of the 4 time points as pair-wise comparisons
(with log2 Ratio (L2R) and B value), EDGE p value, GO cellular
component annotation; ref reference.
(PDF)
Table S3 qPCR analysis of PF10_0017 and PFB0105c
using genomic DNA and cDNA templates from V1SLM
and V1S P. falciparum isolates. cDNA samples were taken at
the 36 h time point. All data were normalised to PF10_0210.
(DOCX)
Table S4 List of primers used for RT-qPCR and qPCR
assays.
(DOCX)
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